DARA BioSciences to Present at the ROTH Growth Stock Conference



    RALEIGH, N.C., Feb. 4 /CNW/ -- DARA BioSciences, Inc. today announced
that the Company will present at the ROTH 20th Annual Growth Stock Conference
in Dana Point, CA on Tuesday, February 19, 2008 at 3:30pm Pacific.
    Interested parties can access a live web cast of the presentation at
www.darabiosciences.com. A replay of the presentation will be available at the
same location.
    
    About DARA BioSciences, Inc.
    
    DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based
development-stage pharmaceutical company that acquires promising therapeutic
molecules and medical technologies directly or through investment in
established companies. DARA focuses its therapeutic development efforts on
small molecules from late preclinical development through phase 2 clinical
trials. DARA is developing a portfolio of therapeutic candidates for
neuropathic pain, metabolic diseases including type 2 diabetes, and
dermatological disorders.
    
    Additional Information and Where to Find It
    
    On October 9, 2007, DARA entered into a definitive agreement to merge
with Point Therapeutics, Inc. (Nasdaq:   POTP) ("Point"). Pursuant to the merger
agreement, DARA will merge with DP Acquisition Corp., a newly-formed
subsidiary of Point, with DARA surviving as a wholly-owned subsidiary of
Point. After giving effect to the merger, DARA stockholders will hold 96.4% of
the combined company's outstanding shares of common stock on a fully-diluted
basis, and Point will change its name to DARA BioSciences, Inc. and be based
in Raleigh, North Carolina. For information regarding the proposed merger,
please refer to the registration statement on Form S-4, which contains a joint
proxy statement/prospectus and other relevant materials, filed by Point with
the Securities and Exchange Commission on December 17, 2007. INVESTORS AND
SECURITY HOLDERS OF POINT AND DARA ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS AND THE OTHER RELEVANT MATERIALS BECAUSE THEY CONTAIN
IMPORTANT INFORMATION ABOUT DARA, POINT AND THE MERGER. The joint proxy
statement/prospectus and other relevant materials and any other documents
filed by Point with the SEC, may be obtained free of charge at the SEC's web
site at www.sec.gov. In addition, investors and security holders may obtain
free copies of the documents filed with the SEC by Point by directing a
request to: Point Therapeutics, Inc., 70 Walnut Street, Wellesley Hills, MA
02481, Attention: Investor Relations.
    For more information regarding DARA, please call 919-872-5578 or visit
our web site at www.darabiosciences.com.
    Please Note: This press release contains forward-looking statements
regarding future events. These statements are just predictions and are subject
to risks and uncertainties that could cause the actual events or results to
differ materially. These risks and uncertainties include the risk that the
merger with Point Therapeutics, Inc. described above will not be consummated,
risks of testing of drugs for proof of principle, risks of regulatory review
and clinical trials, competition, market acceptance for approved products, if
any, and intellectual property risks.




For further information:

For further information: Lynn H. Morris, Sr. Manager, Investor Relations
&  Corporate Operations of DARA BioSciences, Inc., +1-919-872-5578 Web Site:
http://www.darabiosciences.com

Organization Profile

DARA BIOSCIENCES, INC.

More on this organization

POINT THERAPEUTICS, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890